Newsroom

UneEN-Sica
Vidéos

Antibiogo : Routine implementation within the MSF Sica Laboratory in Bagui, CAR

UneAi4CC_video
Vidéos

Cervical cancer: detect better, detect earlier with the help of AI, report in Malawi

Articles

Cervical cancer : when AI helps improve diagnosis

Cervical cancer is the second deadliest cancer in low- and middle-income countries (1). In Malawi in East Africa, where MSF operates, over 4,000 Malawian women fall sick with cervical cancer every year. With 2,905 deaths due to cervical cancer in 2020, the country also had the second highest rate of mortality (2). How can we explain such a high mortality rate from this disease which, in high-income countries, is easily preventable and generally less deadly?  The reasons include limited access to prevention and screening, and diagnoses that are not always reliable.

 

Clara Nordon, Director of the MSF Foundation, has just got back from a visit to Malawi with the MSF teams and tells us about the project led by the Foundation. Code name: AI4CC

Read more
IrakExploEn_une
Vidéos

The MSF Foundation is exploring patient follow-up possibilities in Baghdad and northern Iraq

UneMotionAntibiogo
Vidéos

All about Antibiogo, a free application to counter AMR

Utilisation d'Antibiogo au laboratoire MSF, hôpital CHK.Kinshasa. République Démocratique du Congo
Articles

Antibiogo is already implemented in routine in DRC and Jordan, and soon within other MSF’s Labs !

Read more

Headline

MSF
Articles

Palestine: MSF responds to the Israeli government's smear campaign

For several days, Médecins Sans Frontières and the MSF Foundation have been the target of an online smear campaign.

Keywords associated with our organizations have been misused in several countries to direct internet users to a disinformation website.

In this context, we are sharing MSF’s statement and reaffirming our commitment to continue our humanitarian work with the populations we support.

Read more

MSF Foundation in Video

News

Publications

  • Publications

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more
  • Publications

    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Read more

Press Review

No news for now.